The platform improves the precision and safety of CRISPR-Cas9 gene editing in human hematopoietic stem and progenitor cells (HSPCs), a development that addresses the long-standing difficulty of ensuring that edited stem cells carry only the intended genetic change. The post SMArT Platform Improves Safety and Efficiency of CRISPR Editing in HSPCs appeared first on Inside Precision Medicine .